History of research and development of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab

被引：0
|
作者：
Yoshida, Takao [1 ]
机构：
[1] Ono Pharmaceut Co Ltd, Reserch Ctr Oncol, Osaka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SE2-4
引用
收藏
页码：693 / 693
页数：1
相关论文
共 50 条
  • [41] Anti-PD-1 antibody treatment for melanoma
    Ribas, Antoni
    Kirkwood, John M.
    Flaherty, Keith T.
    LANCET ONCOLOGY, 2018, 19 (05): : E219 - E219
  • [42] A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient
    Jodai, Takayuki
    Yoshida, Chieko
    Sato, Ryo
    Kakiuchi, Yosuke
    Sato, Nahoko
    Iyama, Shinji
    Kimura, Tomoko
    Saruwatari, Koichi
    Saeki, Sho
    Ichiyasu, Hidenori
    Fujii, Kazuhiko
    Tomita, Yusuke
    IMMUNITY INFLAMMATION AND DISEASE, 2019, 7 (01) : 3 - 6
  • [43] Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions
    Jour, George
    Glitza, Isabella C.
    Ellis, Rachel M.
    Torres-Cabala, Carlos A.
    Tetzlaff, Michael T.
    Li, Janet Y.
    Nagarajan, Priyadharsini
    Huen, Auris
    Aung, Phyu P.
    Ivan, Doina
    Drucker, Carol R.
    Prieto, Victor G.
    Rapini, Ronald P.
    Patel, Anisha
    Curry, Jonathan L.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (08) : 688 - 696
  • [44] Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer
    Rogado, Jacobo
    Pozo, Fernando
    Troule, Kevin
    Sanchez-Torres, Jose Miguel
    Romero-Laorden, Nuria
    Mondejar, Rebeca
    Donnay, Olga
    Ballesteros, Anabel
    Pacheco-Barcia, Vilma
    Aspa, Javier
    Al-Shahrour, Fatima
    Alfranca, Arantzazu
    Colomer, Ramon
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (11): : 2241 - 2249
  • [45] Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
    Woo, Taylor E.
    Stukalin, Igor
    Ding, Philip Q.
    Goutam, Siddhartha
    Sander, Michael
    Ewanchuk, Benjamin
    Cheung, Winson Y.
    Heng, Daniel Y. C.
    Cheng, Tina
    CURRENT ONCOLOGY, 2023, 30 (10) : 8936 - 8947
  • [46] Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody
    Miura, Risako
    Sawada, Shin-ichi
    Mukai, Sada-atsu
    Sasaki, Yoshihiro
    Akiyoshi, Kazunari
    RSC ADVANCES, 2020, 10 (14) : 8074 - 8079
  • [47] Excess weight and anti-PD-1 immune checkpoint inhibitor’s outcomes in non-small cell lung cancer
    Jacobo Rogado
    Fernando Pozo
    Kevin Troulé
    José Miguel Sánchez-Torres
    Nuria Romero-Laorden
    Rebeca Mondejar
    Olga Donnay
    Anabel Ballesteros
    Vilma Pacheco-Barcia
    Javier Aspa
    Fátima Al-Shahrour
    Arantzazu Alfranca
    Ramon Colomer
    Clinical and Translational Oncology, 2022, 24 : 2241 - 2249
  • [48] Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
    Liang, Xiaowei
    Gao, Hongwei
    Xiao, Jian
    Han, Shan
    He, Jia
    Yuan, Renyikun
    Yang, Shilin
    Yao, Chun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [49] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies (vol 26, pg 2375, 2015)
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1362 - 1362
  • [50] Biomarkers for Response to Anti-PD-1/Anti-PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
    Mariam, Arshiya
    Kamath, Suneel
    Schveder, Kimberly
    McLeod, Howard L.
    Rotroff, Daniel M.
    ONCOLOGY-NEW YORK, 2023, 37 (05): : 210 - 219
12345